Abstract
Case Description—3 dogs (9 to 12 years old) were evaluated because of recurrent pleural effusion that was refractory to treatment of the underlying cause.
Clinical Findings—Dogs were evaluated because of cough, dyspnea, tachypnea, or lethargy or a combination of these clinical signs. Radiography, ultrasonography, or thoracocentesis were used to confirm the presence of pleural fluid in each dog. A neoplastic cause of pleural effusion was confirmed in 2 dogs. In 1 dog, fasciitis of the mediastinum and the left parietal pleura was diagnosed, with no evidence of neoplasia.
Treatment and Outcome—Each dog was anesthestized, and thoracotomy was performed with manual perforation of the mediastinum. Permanent, subcutaneously placed vascular access ports were attached to intrathoracic, Jackson-Pratt drain tubing for repeated drainage of pleural fluid. Drains were used successfully in the 3 dogs for periods of 6 weeks, 11 weeks, and > 3 years.
Clinical Relevance—Findings suggest that subcutaneous vascular access ports attached to intrathoracic drain tubing may be an effective way to remove recurrent pleural effusion in dogs.
A10-year-old 7.1-kg (15.6-lb) spayed female Jack Russell Terrier (dog 1) was referred to the CUHA for evaluation of pleural effusion. The dog was initially examined by the referring veterinarian because of cough and increased respiratory effort of several weeks' duration. Thoracic radiography revealed pleural effusion. Via thoracocentesis, 180 mL (25.3 mL/kg [11.5 mL/lb]) and 120 mL (16.9 mL/kg [7.7 mL/lb]) of fluid was removed from the left and right hemithorax, respectively. The fluid was characterized cytologically as a modified transudate.
Physical examination findings at the CUHA were unremarkable. Results of CBC, serum biochemical analyses, and urinalysis were within reference limits. No cause for the pleural effusion was identified by use of thoracic ultrasonography, echocardiography, or computed tomography of the thorax. Thoracoscopic evaluation revealed thickening of the mediastinum and the left cranial parietal pleura. Biopsy specimens of the abnormal tissue were obtained, and histologic evaluation revealed mild monocytic and neutrophilic fasciitis of the mediastinum and the left parietal pleura, with no evidence of neoplasia. The dog was discharged from CUHA. During the next 2 weeks, the referring veterinarian removed fluid via thoracocentesis on 4 occasions.
Eighteen days after the initial evaluation, the dog was returned to the CUHA for surgical treatment of persistent pleural effusion. A left, fifth intercostal thoracotomy was performed, and a small amount of pleural fluid was removed via suction. The mediastinum was perforated by use of blunt dissection, and a Jackson-Pratt draina was placed through the perforation so that it spanned from the left to the right pleural cavity. The Jackson-Pratt drain tubing was connected to the indwelling catheter portion of a VAPb by insertion of the smaller-diameter catheter tubing into the Jackson-Pratt tubing. The connection was secured by placement of 2 to 3 encircling ligatures of nonabsorbable, monofilament suture material (Figure 1). A 4-cm-long dorsoventral skin incision was made over the left lateral cervical area, and a subcutaneous pocket was made just caudal to the skin incision. A VAP injection port was secured to left dorsal cervical muscle fascia within the subcutaneous pocket by use of nonabsorbable, monofilament suture material. The VAP catheter was passed out of the thorax through a small incision in the fourth intercostal space. The catheter was then tunneled through the intercostal muscles and subcutaneous tissue to the cervical site and connected to the injection port (Figure 2). Patency of the system was assessed via injection of sterile saline (0.9% NaCl) solution containing heparin into the injection port prior to closure. Routine closure of the thoracotomy was performed by use of interrupted, circumferential, absorbable sutures. The subcutaneous tissue over the injection port was closed with absorbable suture in a simple interrupted pattern. At the incision site, skin edges were apposed with nylon sutures in a simple interrupted pattern.
Photograph of a VAP designed for subcutaneous placement (circular device to right of image) that is connected to a Jackson-Pratt drain.
Citation: Journal of the American Veterinary Medical Association 230, 4; 10.2460/javma.230.4.527
Illustration depicting placement of a VAP and Jackson-Pratt drain for treatment of pleural effusion in a dog (viewed from left side). Notice the cervical subcutaneous location of the VAP and the intrathoracic location of the Jackson-Pratt drain.
Citation: Journal of the American Veterinary Medical Association 230, 4; 10.2460/javma.230.4.527
Beginning 7 days after placement, the VAP was used to drain 25 to 100 mL (3.5 to 14.1 mL/kg [1.6 to 6.4 mL/lb]) of pleural fluid once weekly for 36 weeks. For each use of the VAP, the overlying skin was scrubbed 3 times with antiseptic soap and alcohol rinses. The skin and septum of the VAP were then punctured with a 22-gauge Huber-point needle, and the effusion was drained. Following drainage, the VAP was flushed with 3 to 5 mL of saline solution containing heparin. On 2 occasions, the pleural fluid was more opaque in appearance and was submitted for microbial culture and anti-microbial susceptibility testing. Bacterial cultures of the fluid collected on the first and second occasion yielded growth of Proteus spp and Pseudomonas spp, respectively. Both infections were treated successfully with amoxicillin-clavulanic acidc (17.5 mg/kg [8 mg/lb], PO, q 12 h, prescribed indefinitely). In addition, ampicillin (28 mg/kg [12.7 mg/lb]) was injected into the pleural space via the VAP once weekly. The VAP hub was reported to have shifted slightly from its original location during the first 6 months of its use, but no other VAP-associated complications developed. Follow-up was obtained 36 months after placement of the VAP; at that time, the VAP was still being aspirated every week, and approximately 25 mL of fluid was removed at each visit.
A 12-year-old 5.2-kg (11.4-lb) spayed female mixed-breed dog (dog 2) was referred to the CUHA for evaluation of a splenic mass. One week prior to evaluation, the dog was examined by the referring veterinarian because of inappetence. Radiographic and ultrasonographic evaluations of the abdomen revealed a splenic nodule. Physical examination findings at the CUHA revealed abdominal distension and sublumbar lymph node enlargement. Results of a CBC, serum biochemical analyses, and urinalysis were unremarkable. Similarly, findings of thoracic radiography were unremarkable. Abdominal ultrasonography revealed 3 to 5 heterogeneously echoic splenic nodules and multiple large lymph nodes. Aspirate specimens of the abnormal splenic and lymph node tissues underwent cytologic examination and immunophenotyping, and results were consistent with CD3-positive, T-cell lymphoblastic lymphoma. Results of cytologic examination of a bone marrow aspirate were negative for lymphoma.
A combination chemotherapy protocol involving L-asparaginased (400 U/kg [181.8 U/lb], SC) and vincristinee (0.5 mg/m2 of body surface area, IV) was initiated. Chemotherapy treatments were given once weekly for the first 4 treatments. The dog was hospitalized for observation during the first treatment and discharged to the owner's care 3 days later. One day after discharge, the dog was returned to the hospital for evaluation because of lethargy, dyspnea, and occasional cough. Evaluation of thoracic radiographs revealed moderate pleural fluid and consolidation of the accessory lung lobe. Results of cytologic examination of a bronchoalveolar lavage specimen were unremarkable. The dog was treated with cephalexin (22 mg/kg [10 mg/lb], PO, q 8 h). At scheduled recheck examination 1 week later, findings of thoracic radiography were consistent with moderate pleural effusion. Abdominal ultrasonography revealed progressive resolution of abdominal lymphadenopathy and splenic masses. No abnormalities were detected echocardiographically. Approximately 40 mL (7.7 mL/ kg [3.5 mL/lb]) of fluid was removed via thoracocentesis performed with a winged infusion set and syringe; cytologically, the fluid was a mature lymphocytic effusion, consistent with chyle. Results of bacterial culture of the pleural fluid were negative.
During the following 4 weeks, the dog required thoracocentesis on 6 occasions to relieve dyspnea. Because lymphoma appeared to be responding to chemotherapy but chylous effusion persisted, a subcutaneous VAP attached to a pleural Jackson-Pratt drain was implanted to facilitate fluid removal. The dog was anesthetized, and the thoracic duct was ligated through a right, ninth intercostal thoracotomy. The mediastinum was perforated for transpleural placement of Jackson-Pratt drain tubing, which was attached to a VAP, as described for dog 1. The VAP was implanted subcutaneously over the right 12th intercostal space. The skin overlying the VAP was aseptically prepared (as described for dog 1), and the VAP was used daily for pleural drainage for the first 2 weeks, then every other day for 1 week. The VAP was flushed with 3 to 5 mL of saline solution containing heparin after each use. Three weeks after implantation, it became difficult to aspirate fluid through the port. Fluoroscopic imaging revealed no obstruction when iodinated contrast material was injected through the port (Figure 3). Nevertheless, as a prophylactic measure, tissue plasminogen activator (0.15 mg/kg [0.07 mg/lb]) was injected into the port, followed 30 minutes later by a flush with saline solution containing heparin. The port continued to be patent, and pleural fluid was drained 1 to 5 times weekly (quantities of pleural fluid removed ranged from 0 to 250 mL (0 to 48.0 mL/kg [0 to 21.8 mL/lb]) until the dog was euthanized because of progressive lymphoma 11 weeks after port placement.
Ventrodorsal fluoroscopic view of the thorax of a dog in which an intrathoracic drain and subcutaneous VAP (not in view) had been placed for the treatment of pleural effusion.
Citation: Journal of the American Veterinary Medical Association 230, 4; 10.2460/javma.230.4.527
A 9-year-old 35-kg (77-lb) spayed female mixedbreed dog (dog 3) was referred to the CUHA for evaluation because of sudden onset of tachypnea and dyspnea. Findings of thoracic radiography were compatible with severe pleural effusion. By use of a closed system comprised of a winged infusion set, 3-way stopcock, and syringe, thoracocentesis was performed twice during the initial evaluation. The dog's clinical signs improved after 1,300 mL (37.1 mL/kg [16.9 mL/lb]) of opaque pleural fluid was drained from the thorax. Cytologic analysis of the fluid revealed a predominance of macrophages, small lymphocytes, and neutrophils. The cytologic diagnosis was inflammation, hemorrhage, and probable chylous pleural effusion. There was no cytologic evidence of neoplasia. Results of a CBC and serum biochemical analyses were unremarkable.
Echocardiographic findings were within reference limits. Abdominal ultrasonography revealed 1 cystic liver mass and numerous fluid-filled masses adjacent to the aorta and renal arteries as well as mild peritoneal fluid. Cytologic examination of an ultrasound-guided fineneedle aspirate of the liver mass revealed many small lymphocytes.
The dog was reexamined 2 weeks later, and mild dyspnea was again evident. Thoracocentesis was not performed at that time. The dog was anesthetized, and thoracostomy tubesf were placed bilaterally. Approximately 2,700 mL (77.1 mL/kg [35.0 mL/lb]) of chylousappearing fluid was removed from the right tube, and 150 mL (4.3 mL/kg [2.0 mL/lb]) of similar fluid was removed from the left tube. A standard ventral midline surgical approach was made for exploration of the abdomen, which revealed a 2-cm, fluid-filled lesion on the surface of the left lateral liver lobe. Incisional biopsy of this cystlike structure was performed, and the wedgeshaped defect was sutured to control hemorrhage. The remainder of the abdominal organs appeared grossly normal. Histologic evaluation of the specimen of liver mass revealed markedly altered tissue architecture with broad, irregular mats of compacted fibrin and extravascular spaces containing free erythrocytes. A single layer of endothelium was comprised of cells that contained ovoid nuclei; those endothelial cells reacted positively with cytoplasmic stain against von Willebrand's factor (factor VIII-related antigen). Histomorphologic diagnosis was lymphangiosarcoma. Thoracostomy tubes were removed following intrapleural administration of carboplatin (250 mg/m2 of body surface area, once only).
Following surgery, the dog was treated with doxorubicin (30 mg/m2 of body surface area, IV, q 3 wk) and fed a homemade low-fat diet with supplements of rutin (43 mg/kg [19.5 mg/lb], PO, q 8 h) and medium-chain triglyceride oil (0.5 mL/kg [0.2 mL/lb], PO, q 24 h). Despite treatment, the dog became dyspneic 8 weeks later and 3 L (85.7 mL/kg [39.0 mL/lb]) of chylous fluid was removed from the pleural space via thoracocentesis performed with a winged infusion set and syringe. A second exploratory laparotomy and thoracotomy for ablation of the cisterna chyli and ligation of the thoracic duct, respectively, were performed. At the time of laparotomy, a peritoneal dialysis draing was placed in the abdomen to drain accumulated fluid and tunneled through the subcutaneous tissue to the caudal thoracic wall, where it was connected to a VAP. In addition, a Jackson-Pratt drain was placed in the pleural cavity via a right, seventh intercostal thoracotomy and connected to a subcutaneous VAP secured to the muscle fascia over the dorsal third portion of the second and third ribs on the right side of the thorax. The mediastinum was perforated so that the pleural drain spanned both sides of the pleural cavity.
Subsequent to placement of the drains, the dog was reexamined weekly for 5 weeks. On all occasions, the dog's behavior appeared normal and both the thoracic and peritoneal drains were successfully used to remove effusions. The overlying skin was prepared, and the VAP was accessed with a Huber-point needle, as described for dog 1. Saline solution containing heparin (3 to 5 mL) was used to flush the VAP after each use. The quantity of fluid drained from the thoracic port ranged from 1,700 to 3,000 mL/visit (48.6 to 85.7 mL/kg [22.1 to 39.0 mL/lb]/visit). After each port was used for drainage, the reservoirs were flushed with saline solution containing heparin.
Six weeks after placement of the drains, the dog became lethargic and inappetent and vomited once. On physical examination, the dog had signs of depression and was weak and febrile (rectal temperature, 39.5°C [103.1°F]). Abdominal ultrasonography revealed fluiddistended, corrugated loops of small intestines; diffusely hyperechoic mesenteric fat; and a hypoechoic pancreas, all of which were suggestive of peritonitis. Cytologic analysis of the abdominal effusion revealed a predominance of neutrophils and intracellular rodshaped bacteria. Cytologic diagnosis was consistent with septic peritonitis. Further treatment was declined by the owners, and the dog died at home 2 days later.
Discussion
The most common causes of pleural effusion in dogs include pyothorax, idiopathic chylous effusion, neoplasia, heart disease, or pulmonary disease.1 Moderate to large amounts of pleural effusion can result in respiratory distress as a result of reduced functional reserve capacity in the lungs2 or cardiovascular dysfunction as a result of cardiac tamponade.3
Several techniques for treatment of pleural effusion in dogs and cats have been reported.2,4–9 Thoracocentesis can be diagnostic and therapeutic, but drainage of persistent effusion requires repeated penetration of the thoracic cavity. Thoracostomy tubes provide continuous or intermittent pleural drainage over an extended period; however, ascending infection, pain, tube failure, or tube removal or damage by the patient can limit the duration of their use.2 Idiopathic chylothorax and some neoplastic pleural effusions can be treated via thoracotomy or thoracoscopic procedures to remove the primary cause. Neoplastic effusions may potentially respond to treatment with systemic or intracavitary chemotherapy.4 Pleurodesis can be used for treatment of chronic pleural effusions, but this method is painful and the results are inconsistent.5,6 Pleuroperitoneal or pleurovenous shunting transfers pleural fluid from the pleural space to the peritoneal cavity or caudal vena cava, respectively.7–9 However, shunting is contraindicated for neoplastic effusions, and clinical effectiveness in veterinary patients has been equivocal.8,9
The VAP was first developed for delivery of chemotherapeutic drugs to humans with cancer.10–13 In veterinary medicine, VAPs are used for delivery of drugs as well as for blood sample collection.14–17 The VAP consists of 2 parts: an indwelling catheter for insertion into a vessel and a subcutaneously placed injection port.18 The injection port is accessed through the skin by use of a specially designed Huber-point needle, which allows repeated puncture of the port without compromise of the integrity of the rubber diaphragm.18 In veterinary medicine, the VAP catheter is most commonly placed in a jugular vein.14
To the authors' knowledge, these are the first reports of use of permanent subcutaneous access ports connected to intrathoracic Jackson-Pratt drains for treatment of chronic, refractory pleural effusion in dogs. In dog 1, the drain is known to have remained functional and patent for > 3 years. In dogs 2 and 3, the drains were used successfully for 6 and 11 weeks, respectively. This treatment should be considered palliative. Primary treatment of the underlying problem is the first line of therapeutic intervention for most pleural effusion cases. The prognosis with regard to the underlying disease should be carefully discussed with owners prior to drain and port placement.
Intrathoracic drains and subcutaneous access ports are relatively simple to place during thoracotomy. If thoracotomy or thoracoscopy is not intended for diagnostic or therapeutic purposes, intrathoracic port placement would require use of a trocar or separate thoracotomy. In dogs and cats, the mediastinum may be complete, requiring placement of bilateral drains or manual fenestration of the mediastinum for treatment of bilateral pleural disease.2 In the dogs of this report, no intraoperative complications were encountered.
Vascular access ports are designed for repeated use. Among the 3 dogs described in this report, a functional VAP remained in place for 6 weeks and was used for at least once-weekly aspiration of fluid in 1, remained in use for > 3 years in another, and remained in daily or every-other-day use for 11 weeks in the third. Complications developed in 2 dogs and included infection and partial port obstruction. Dog 3 died as a result of septic peritonitis; on questioning, the owners reported that they had repeatedly used nonsterile technique in attempting to aspirate fluid from the subcutaneous port attached to the peritoneal drain. A low incidence of catheter-related infection has been reported with the use of VAPs, and nonsterile technique would presumptively increase the risk of infection.17,19–21 Infection of a VAP or any implanted device is best treated by surgical removal of the implant.17,21 Prophylactic administration of antimicrobials in routine VAP maintenance is not recommended.17 Difficulty in aspirating or flushing VAPs in various species has been previously reported.17,19 Fluoroscopy was used to assess possible port obstruction in the second dog of this report, and tissue plasminogen activator was administered to dissolve blood clots suspected to be present within the port.
It is possible that the small volume of pleural fluid drained from dog 1 during weekly evaluations was secondary to the presence of the drain in the pleural space.2 If the pleural effusion decreases in volume or resolves almost completely, continued pleural drainage may not be necessary; lymphatic drainage may provide adequate elimination of small volumes of fluid from the pleural space.22 However, unless infection is present, removal of the intrathoracic drain is not indicated, particularly if relapse of the disease process is possible.
The use of a VAP for pleural drainage has multiple potential benefits. The small diameter of the VAP catheter appears to result in less discomfort than a conventional thoracostomy tube. Following normal postoperative healing, the VAP also eliminates inflammation and signs of pain associated with long-term, repeated thoracocentesis. The VAP is implanted subcutaneously, thereby reducing the risk of ascending infection associated with thoracostomy tubes. Finally, the risk of pulmonary tissue damage associated with repeated thoracocentesis is eliminated with the use of a VAP for pleural drainage.
Recently, a port has been designed specifically for drainage of pleural effusion in small animal patients.h This port eliminates the need for Jackson-Pratt drain tubing and intraoperative connection to the VAP. Future studies are necessary to determine the success of pleural port use. However, findings in the dogs of this report suggest that pleural ports may provide successful, palliative treatment of chronic pleural effusion.
ABBREVIATIONS
CUHA | Cornell University Hospital for Animals |
VAP | Vascular access port |
Jackson-Pratt, Cardinal Health, McGaw Park, Ill.
The companion port, Norfolk Vet Products, Skokie, Ill.
Clavamox, Pfizer Animal Health, Exton, Pa.
Elspar, Merck & Co, West Point, Pa.
Oncovin, Eli Lilly & Co, Indianapolis, Ind.
Pleur-evac thoracic catheter, Teleflex Medical, Durham, NC.
Peritoneal dialysis drain, PhysioControl, Redmond, Wash.
PleuralPort, Norfolk Vet Products, Skokie, Ill.
References
- 1↑
Mellanby RJ, Villiers E, Herrtage ME. Canine pleural and mediastinal effusions: a retrospective study of 81 cases. J Small Anim Pract 2002;43:447–451.
- 2↑
Monnet E. Pleura and pleural space. In:Slatter D, ed.Textbook of small animal surgery. 3rd ed.Philadelphia: WB Saunders Co, 2002;387–405.
- 3↑
Little AA, Steffey MA, Kraus MS. Marked pleural effusion causing right atrial collapse simulating cardiac tamponade in a dog. J Am Anim Hosp Assoc 2007;in press.
- 4↑
Moore AS, Kirk C, Cardona A. Intracavitary cisplatin chemotherapy experience with six dogs. J Vet Intern Med 1991;5:227–231.
- 5
Laing EJ, Norris AM. Pleurodesis as a treatment for pleural effusion in the dog. J Am Anim Hosp Assoc 1986;22:193–196.
- 6
Birchard SJ, Gallagher L. Use of pleurodesis in treating selected pleural diseases. Compend Contin Educ Pract Vet 1988;10:826–832.
- 7
Smeak DD, Gallagher L, Birchard SJ, et al. Management of intractable pleural effusion in a dog with pleuroperitoneal shunt. Vet Surg 1987;16:212–216.
- 8
Smeak DD, Birchard SJ, McLoughlin MA, et al. Treatment of chronic pleural effusion with pleurperitoneal shunts in dogs: 14 cases. J Am Vet Med Assoc 2001;219:1590–1597.
- 9
Willauer CC, Breznock EM. Pleurovenous shunting technique for treatment of chylothorax in three dogs. J Am Vet Med Assoc 1987;191:1106–1109.
- 10
Gyves J, Ensminger W, Niederhuber J, et al. Totally implantable systems for intravenous chemotherapy in patients with cancer. Am J Med 1982;73:841–845.
- 11
Bothe A, Piccione W, Ambrosino JJ, et al. Implantable central venous access systems. Am J Surg 1984;147:565–569.
- 12
Bland KI, Woodcock T. Totally implantable venous access system for cyclic administration of cytotoxic chemotherapy. Am J Surg 1984;147:815–816.
- 13
Niederhuber JE, Ensminger W, Gyves JW, et al. Totally implanted venous and arterial access system to replace external catheters in cancer treatment. Surgery 1982;92:706–712.
- 14↑
Bagley RS, Flanders JA. The use of totally implantable vascular access systems. Compend Contin Educ Pract Vet 1990;12:22–27.
- 15
Rassnick KM, Gould WJ, Flanders JA. Use of a vascular access system for administration of chemotherapeutic agents to a ferret with lymphoma. J Am Vet Med Assoc 1995;206:500–504.
- 16
Henry CJ, Russell LE, Tyler JW, et al. Comparison of hematologic and biochemical values for blood samples obtained via jugular venipuncture and via vascular access ports in cats. J Am Vet Med Assoc 2002;220:482–485.
- 17↑
Swindle MM, Nolan T, Jacobson A, et al. Vascular access port (VAP) usage in large animal species. Contemp Top Lab Anim Sci 2005;44:7–17.
- 18↑
Dalton MJ. The vascular port—a subcutaneously implanted drug delivery depot. Lab Anim 1985;15:21–30.
- 19
Webb AI, Bliss JM, Herbst LH. Use of vascular access ports in the cat. Lab Anim Sci 1995;45:110–114.
- 20
Coccaro M, Bochicchio AM, Capobianco AML, et al. Long-term infusional systems: complications in cancer patients. Tumori 2001;87:308–311.
- 21
Wolosker N, Yazbek G, Munia MA, et al. Totally implantable femoral vein catheters in cancer patients. Eur J Surg Oncol 2004;30:771–775.
- 22↑
Noone KE. Pleural effusions and diseases of the pleura. Vet Clin North Am Small Anim Pract 1985;15:1069–1085.